ArticleMolecular and clinical oncology2026
Prognostic value and predictive biomarkers of synergistic interaction between tumor-associated macrophages and cancer stem cells in colorectal cancer.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Role of Musashi-2 Immunohistochemical Expression and CD163+ Tumor- Associated Macrophages in Colorectal Cancer Progression.Asian Pacific journal of cancer prevention : APJCP · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) and tumor-associated macrophages (TAMs) are associated with the prognosis of colorectal cancer (CRC). Emerging studies indicate active crosstalk between CSCs and TAMs within the tumor microenvironment. However, the prognostic implications of integrating CSC- and TAM-associated markers for risk stratification remain incompletely defined in CRC. Expression levels of CD86, CD163, CD44 and CD133 were assessed by immunohistochemistry. Pearson s chi-square test was employed to analyze correlations between marker expression and clinicopathological parameters. The Kaplan-Meier method and log-rank test were used to determine survival differences and identify potential prognostic factors. Variables achieving statistical significance (P<0.05) in the univariate analysis were subsequently included in a multivariate Cox proportional hazards regression model to analyze independent predictors of overall survival. The results demonstrated that a combined expression profile of high CD86 with low CD163, CD44 and CD133 was significantly associated with prolonged survival. CD86 expression was negatively correlated with CD133 and CD44, while CD163 showed positive correlations with both markers. In addition, elevated CD163 and CD133 levels were positively correlated with poorer prognosis in patients with CRC. In conclusion, it was suggested that different TAM phenotypes in combination with CSC-related biomarkers serve as potential biomarkers for CRC onset and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.